Allergy & Asthma Network Mothers of Asthmatics Applauds FDA Public Health
Advisory and Offers Critical Facts Patients Need to Know
FAIRFAX, Va., May 30 /PRNewswire-USNewswire/ -- Millions of asthma patients and their healthcare providers do not know that at the end of this year, their life-saving medications will be gone. Today, FDA urged patients still using chlorofluorocarbon (CFC) albuterol metered-dose inhalers (MDIs) to switch to alternate hydrofluoroalkane (HFA) inhalers (albuterol and levalbuterol) before CFCs are completely off the market. As of December 31, 2008, no CFC albuterol inhalers will be manufactured or sold in this country.
CFC is used to propel medication from asthma inhalers into patients' airways. But it also depletes the earth's ozone layer, so it's being phased out of medications like inhaled albuterol, one of the top 10 prescriptions written in the United States. Patients with asthma, COPD and other respiratory conditions use albuterol at the first sign of symptoms, before exercise and when experiencing breathing exacerbations. Alternate inhalers using HFA as a propellant are replacing CFC albuterol.
"We applaud FDA's efforts to educate patients and medical professionals
about the new HFA inhalers," states Nancy Sander, president and founder of
Allergy & Asthma Network Mothers of Asthmatics (AANMA). "There are critical
differences between CFC and HFA inhalers that patients need to know in
order to use these medications properly."
-- HFA MDIs have a softer spray. Some patients comment that force of the
HFA propellant is not strong enough to "push open" their airways during
an attack. But it is the correct inhalation technique, not the force of
the propellant, that determines how well the medication works. Neither
type of inhaler can push or force airways open.
-- HFA MDIs have different cleaning requirements. HFA MDIs need to be
cleaned more frequently than CFC MDIs. HFAs tend to clog more quickly
than CFCs, preventing medication from reaching patients' airways.
-- HFA MDIs have different priming requirements. Priming (spraying
multiple doses into the air) loads the correct dose of medication
inside the inhaler. Each HFA inhaler has different priming
instructions, which can be quite different from CFC priming.
-- HFA MDIs offer more treatment options. In the past, all brand and
generic albuterol CFC MDIs were virtually identical. Now there are
three uniquely different formulations of albuterol HFA inhalers plus a
levalbuterol HFA inhaler -- each distinctly different from the others.
Some people may find that one HFA inhaler works better for them than
-- HFA MDIs cost more than generic CFC albuterol MDIs. HFA MDIs are not
simply copies of CFC MDIs with new propellants. The inhaler transition
required a complete overhaul of the MDI manufacturing process. No
generic HFA MDIs are currently available. This translates to higher
out-of-pocket expenses for many patients, even those with prescription
drug coverage. Pharmaceutical companies are providing financial
assistance to patients in the form of rebates, discounts and coupons
and patient assistance programs.
"These are lifesaving medications," says Sander. "Patients and medical
professionals need to know that inhalers are changing and have the
opportunity to make the switch in a medically responsible way. Our advice
to patients: Get the facts. Know your options. Make informed choices."
Visit AANMA's MDI Transition Web page at http://www.breatherville.org/MDITransition for more information.
Founded in 1985, Allergy & Asthma Network Mothers of Asthmatics is the leading national nonprofit family organization dedicated to eliminating suffering and death due to asthma, allergies and related conditions. AANMA's core areas of expertise are education, advocacy and outreach. Call 800.878.4403 or visit http://www.breatherville.org.
|SOURCE Allergy & Asthma Network Mothers of Asthmatics|
Copyright©2008 PR Newswire.
All rights reserved